-
Beijing Wantai Receives NMPA Clearance for Nine-Valent HPV Vaccine Targeting Male Population
•
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading Chinese pharmaceutical company, has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its nine-valent human papillomavirus (HPV) vaccine (Escherichia coli), specifically designed for the male population. Global Impact and Vaccine RelevanceGlobally, approximately…
-
CanSino Biologics Initiates Phase I Clinical Trial for Freeze-Dried Hib Conjugate Vaccine
•
China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced the commencement of a Phase I clinical study for its freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine, marking a significant step in the development of this important pediatric vaccine. The study has begun with the enrollment of the first subject,…
-
CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of mRNA Vaccine SYS6026
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its therapeutic bivalent mRNA vaccine, SYS6026. This vaccine is indicated for the treatment of precancerous lesions caused by human papillomavirus (HPV) types 16 or 18. Vaccine…
-
AIM Vaccine Submits Market Filing for 13-Valent Pneumococcal Conjugate Vaccine in China
•
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the submission of a market filing for its in-house developed 13-valent pneumococcal conjugate vaccine to the National Medical Products Administration (NMPA). Streptococcus pneumoniae disease is a high-priority target for vaccine prevention efforts. The 13-valent pneumococcal conjugate vaccine is designed for infants…
-
AIM Vaccine Secures NMPA Approval for mRNA Vaccine Targeting RSV
•
AIM Vaccine Co., Ltd (HKG: 6660), based in China, has received clinical trial approval from the National Medical Products Administration (NMPA) for its mRNA vaccine targeting respiratory syncytial virus (RSV). RSV is a leading cause of mortality in infants under one year old and significantly contributes to respiratory infections and…
-
Clover Biopharmaceuticals Reports Strong Phase I Results for RSV Vaccine SCB-1019
•
China-based Clover Biopharmaceuticals Ltd. (HKG: 2197) has announced encouraging additional immunogenicity and safety data from its Phase I trial of SCB-1019, a non-adjuvanted bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate. The trial assessed SCB-1019 against GSK (NYSE: GSK)’s AS01E-adjuvanted RSV vaccine, Arexvy, in elderly subjects. In the ongoing Phase…
-
NMPA’s Center for Drug Evaluation Issues New Guidelines for Domestic Transfer of Overseas-Produced Vaccines
•
The Center for Drug Evaluation under the National Medical Products Administration (NMPA) has issued the “Requirements for Application Materials for Market Registration of Listed Drugs Produced Abroad and Transferred to Domestic Production (Preventive Biological Products),” which is set to take effect immediately. This new directive pertains to preventive biological products,…
-
Walvax Biotechnology’s Weuphoria Vaccine Approved in Oman for Pediatric Pneumococcal Infections
•
Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that it has received market approval in the Sultanate of Oman for its vaccine Weuphoria, a 13-valent pneumococcal polysaccharide conjugate vaccine (PCV-13). This approval marks a significant step for the company as it expands the reach of its…
-
Olymvax Bio Receives NMPA Approval for Clinical Study of Trivalent Influenza Vaccine
•
Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its trivalent influenza virus split vaccine (MDCK cells). This vaccine is designed for the prevention of influenza caused…
-
Westgene Biopharma’s Pioneering mRNA Vaccine for EBV-Related Tumors Clears IND Hurdle in China
•
Westgene Biopharma has received approval from the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) in China for its new drug research application (IND) for “WGc-043 Injection.” The approval, dated August 6, 2024, grants Westgene Biopharma the green light to initiate Phase I clinical trials. “WGc-043…
-
Bill & Melinda Gates Foundation Invests $17 Million in CanSino Biologics’ Recombinant Polio Vaccine
•
The Bill & Melinda Gates Foundation has committed USD 17 million to support the development of CS-2036, a recombinant polio vaccine, by China-based CanSino Biologics (SHA: 688185, HKG: 6185). The investment will fund various development efforts, including clinical trials, process development, scaling-up, and the development of a candidate combined vaccine…
-
Pfizer Partners with Shanghai Pharmaceutical for Long-Term Vaccine Collaboration in China
•
Pfizer Inc. (NSE: PFIZER, NYSE: PFE, ETR: PFE), a leading pharmaceutical company in the U.S., has entered into a partnership with China’s Shanghai Pharmaceutical Holding Co., Ltd (SHA: 601607; SPH) to establish a long-term collaboration in the vaccine sector. The collaboration will focus on product promotion, introduction of innovative products,…
-
Johnson & Johnson Reportedly Winding Down Cardiovascular and Metabolic Pharma Unit
•
Johnson & Johnson (J&J; NYSE: JNJ), a healthcare giant in the U.S., is reportedly winding down its cardiovascular and metabolic pharmaceutical unit, as reported by Endpoints News. Insiders have indicated that J&J has issued notices to its sales, marketing, and medical affairs teams this week. The company has acknowledged the…
-
GSK Appoints Li Weidong as Vaccine Business Head for China
•
GSK plc (LON: GSK, NYSE: GSK), a leading pharmaceutical company based in the UK, has announced the appointment of Li Weidong to the role of Vice President and Head of Vaccine Business for GSK China. Li will report directly to Sherman Yu, GSK Vice President and General Manager of GSK…
-
Beijing Bohui Innovation Biotechnology Ends Rabies Vaccine Partnership with BOAOVAX
•
Beijing Bohui Innovation Biotechnology Group Co., Ltd. (SHA: 300318), a leading biopharmaceutical company in China, has announced an agreement with BOAOVAX to terminate their collaborative efforts on the development of a freeze-dried human rabies vaccine cultivated using serum-free Vero cells. As per the agreement, all clinical trials related to the…
-
Beijing Bohui Innovation and BOAOVAX End Collaboration on Rabies Vaccine Development
•
Beijing Bohui Innovation Biotechnology Group Co., Ltd. (SHE: 300318), a biopharmaceutical company based in China, has announced an agreement with domestic firm BOAOVAX to terminate their collaboration on the development of a freeze-dried human rabies vaccine cultivated using serum-free Vero cells. As a result of this agreement, the clinical trials…
-
ApolloBio’s HPV Therapeutic Vaccine VGX-3100 Gets NMPA Green Light for Clinical Trial
•
ApolloBio Corp., a joint stock company of China’s leading cephalosporin manufacturer Shandong Jincheng Pharmaceutical and Chemical Co., Ltd (SHE: 300233), has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for VGX-3100. This drug, hailed as the world’s first therapeutic vaccine for human papillomavirus…
-
Beijing Wantai Biological and Fujian Provincial CDC Collaborate on Vaccine Development and Public Health Initiatives
•
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading biopharmaceutical company based in China, has entered into a strategic partnership with the Fujian Provincial Center for Disease Control and Prevention (FJCDC). This collaboration will focus on enhancing efforts in pathogen detection technology, vaccine development, clinical research, scientific outreach,…
-
Chengdu Kanghua Biological Products Inks Five-Year Partnership to Boost Sichuan’s Biotech and Vaccine Industries
•
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has entered into a five-year strategic partnership with Sichuan Biopharmaceutical Industry Group Pharmaceutical Industry Group Co., Ltd and Sichuan Development Leading Capital Management Co., Ltd. The collaboration aims to pool resources and leverage mutual strengths to…
-
Sinocelltech’s Herpes Zoster Vaccine SCTV04C Clears NMPA for Clinical Trial
•
Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has received approval from the National Medical Products Administration (NMPA) to commence clinical trials for SCTV04C, its proprietary recombinant herpes zoster vaccine. Herpes zoster, commonly known as shingles, is an infectious skin condition that results from the reactivation of…
-
Sinopharm and Ruidio Pharmaceutical Advance in Priority Review for Innovative Drugs and Vaccines
•
BEIJING—The Center for Drug Evaluation (CDE) has indicated that two Chinese companies, Foshan Ruidio Pharmaceutical Co., Ltd and Chengdu Institute of Biological Products Co., Ltd., part of Sinopharm, are on the path to priority review for their respective medical innovations. Ruidio’s Technetium [99mTc] hydrazine nicotinamide polyethylene glycol bicyclic RGD peptide…
-
Sanofi Halts Flu Vaccine Distribution in China Amid Potency Concerns
•
Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has reportedly suspended the distribution and sale of its flu vaccines in China following concerns over declining potency identified during routine batch checks. According to FiercePharma.com, which cites an email from a Sanofi spokesperson, the suspension will affect supplies of both Vaxigrip and…
-
Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition
•
Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE: 300142), has released its financial report for the first half of 2024. The company reported operating revenue of RMB 1.433 billion, marking a significant year-on-year (YOY) decrease of 33.88%. The non-net profit attributable to the…
-
Diversifying HPV Protection: Beijing Wantai’s Vaccine Filing Competes with Gardasil 9 in China
•
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange (SHA: 603392), has announced that the National Medical Products Administration (NMPA) has accepted for review the market approval filing for its innovative recombinant human papillomavirus (HPV) vaccine. This nine-valent vaccine, which targets HPV…
-
Takeda Prepares to File Dengue Fever Vaccine for US Approval, Expanding Global Regulatory Reach
•
Takeda Pharmaceutical, a leading Japanese pharmaceutical company listed on the NYSE (NYSE: TAK), is reportedly preparing to submit its dengue fever vaccine for regulatory approval in the United States, according to the Nikkei Asian Review. At this juncture, specifics regarding the timing of the filing or the anticipated decision date…
-
Everest Medicines Launches Trial for Personalized mRNA Cancer Vaccine EVM16 in Solid Tumors
•
Everest Medicines, a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1952), has announced the commencement of an investigator-initiated trial (ITT) for its cutting-edge personalized mRNA cancer vaccine, EVM16. The trial, spearheaded by Beijing Cancer Hospital and Fudan University Shanghai Cancer Center, is a…
-
Chengdu Kanghua Biological Products Reports 16.81% YOY Revenue Growth in H1 2024 Financial Results
•
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has reported its financial results for the first half of 2024, with revenues reaching RMB 741 million (USD 104 million), marking a significant year-on-year (YOY) increase of 16.81%. The net profits attributable to shareholders have risen…
-
Chengdu Kanghua Biological Products Soars with 16.81% YOY Revenue Growth in H1 2024 Report
•
CHENGDU—Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841) has reported a significant upswing in its financial performance for the first half of 2024, with revenues reaching RMB 741 million (USD 104 million), marking a 16.81% increase year-on-year. Net profits attributable to shareholders have also seen robust growth, climbing to RMB…
-
Wantai Biological’s HPV Vaccine Receives Priority Review from China’s CDE
•
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced that its nine-valent recombinant human papillomavirus (HPV) vaccine, co-developed with Xiamen University, has received priority review status from China’s Center for Drug Evaluation (CDE). This vaccine targets seven high-risk HPV types (HPV16, 18, 31, 33, 45, 52, and 58)…
-
GSK Initiates Phase III Study for RSV Vaccine in China Following U.S. Approval
•
GSK (NYSE: GSK), the UK-based pharmaceutical giant, has registered a Phase III bridging study for its recombinant RSV vaccine in China on ClinicalTrials.gov. The vaccine, which received marketing approval in the U.S. in May 2023, will undergo a study that aims to complete its primary endpoint follow-up by March 2025.…
-
WestGene Biopharma’s EB Virus-Targeting mRNA Vaccine WGc-043 Clears for Clinical Trials in China
•
WestGene Biopharma Co., Ltd., a biotechnology company based in Chengdu, has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to proceed with clinical trials for its candidate drug, WGc-043. This marks a significant milestone as WGc-043 is the world’s first mRNA therapeutic…
-
Walvax Biotechnology’s HPV Vaccine Price Cut Sparks Potential Market Price War in China
•
Walvax Biotechnology Co., Ltd (SHE: 300142) has significantly reduced the price of its bivalent human papillomavirus (HPV) vaccine to a record low of RMB 27.5 per dose for domestic products, according to the Shandong Center for Disease Control and Prevention’s disclosure of the 2024 purchase transaction data for the vaccine…
-
GSK Reports Q2 2024 Earnings with 13% Growth, Vaccines Unit Sees Mixed Results
•
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has reported its financial results for the second quarter of 2024, showing a robust year-on-year (YOY) growth of 13% in constant currency terms, reaching £7.88 billion ($10.12 billion). The company’s performance was marked by growth across all business units, with the…
-
Merck’s Q2 2024 Earnings Miss Estimates as China Market Downturn Surprises
•
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has reported its financial results for the second quarter of 2024, with global revenues reaching USD 16.1 billion, marking an 11% increase year-on-year when excluding currency impacts. Despite this growth, the company’s stock price declined by 9.81% as investors reacted to the…
-
CanSino Biologics Partners with Malaysia’s NIBM to Develop mRNA Influenza Vaccine
•
CanSino Biologics Inc. (HKG: 6185), a leading Chinese biotechnology company, has entered into a strategic partnership with the National Institute of Biotechnology Malaysia (NIBM). The collaboration aims to enhance the development, manufacturing, technology transfer, and talent exchange between the two entities, focusing on mRNA multivalent influenza vaccines and the exploration…
-
Innorna’s Herpes Zoster mRNA Vaccine IN001 Receives Clinical Trial Approval in China
•
Shenzhen-based Innorna Co., Ltd has announced that it has received approval from the National Medical Products Administration (NMPA) to commence clinical trials for its proprietary IN001, a novel mRNA vaccine designed to combat herpes zoster. This marks a significant milestone for the company, as IN001 is the first mRNA-based herpes…
-
Innovax Biotech and GSK Terminate Collaboration on Next-Generation HPV Vaccine
•
Xiamen Innovax Biotech Co., Ltd., a Chinese biopharmaceutical company, and GlaxoSmithKline (GSK, NYSE: GSK), a leading UK pharmaceutical giant, have agreed to terminate their alliance for the development and commercialization of next-generation human papillomavirus (HPV) vaccines. The partnership, which began in September 2019, resulted in the creation of HPV9-AS04, a…
-
CSPC Pharmaceutical’s RSV mRNA Vaccine SYS6016 Receives Clinical Trial Approval from NMPA
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its candidate mRNA vaccine, SYS6016, targeting the respiratory syncytial virus (RSV). The vaccine, SYS6016, is designed using mRNA molecules that…
-
Moderna Partners with Mitsubishi Tanabe for mRNA Vaccine Promotion in Japan
•
Moderna Inc. (NASDAQ: MRNA), a leading mRNA specialist biotechnology company based in the U.S., has selected Japan’s Mitsubishi Tanabe Pharmaceutical Corp. to establish a co-promotion partnership for Moderna’s mRNA respiratory vaccine portfolio in the Japanese market. The agreement will encompass the promotion of Moderna’s COVID-19 vaccine, Spikevax, and aims to…
-
GSK Secures Global Rights to CureVac’s mRNA Vaccine Candidates in Expanded Partnership
•
GlaxoSmithKline (GSK, NYSE: GSK) , a UK-based pharmaceutical giant, is poised to expand its partnership with CureVac N.V. (Nasdaq: CVAC), a German mRNA specialist. The revised agreement will grant GSK full global rights to develop, manufacture, and commercialize mRNA candidate vaccines for influenza and COVID-19, encompassing related combination regimens. As…
-
Chengdu-Based Vaccine Specialist Maxvax Biotechnology Raises USD 41.3 Million in Latest Funding Round
•
Maxvax Biotechnology, a leading vaccine-focused biotech company headquartered in Chengdu, has successfully closed its Series C+ financing round, securing over RMB 300 million (USD 41.3 million). This latest funding round was spearheaded by IDG Capital, with significant participation from Hankang Capital and Qianhai Ark Asset Management. The capital raised in…
-
Walvax Biotechnology Halts COVID-19 mRNA Vaccine Trials Co-Developed with Abogen Biosciences
•
Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the termination of clinical trials for a COVID-19 mRNA vaccine that was co-developed with Abogen Biosciences Co., Ltd, a specialized developer of messenger ribonucleic acid (mRNA) drugs. This decision also affects the technology development cooperation between…
-
Clover Biopharmaceuticals’ RSV Vaccine Candidate Shows Promising Results in Elderly
•
Clover Biopharmaceuticals Ltd. (HKG: 2197), a biopharmaceutical company based in China, has announced positive preliminary results from the Phase I clinical study of its pipeline candidate SCB-1019 in the elderly population. The molecule is a respiratory syncytial virus (RSV) PreF trimeric subunit candidate vaccine. A total of 48 subjects were…
-
MSD’s Capvaxive Vaccine Targets 21 Serotypes of Streptococcus Pneumoniae
•
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Capvaxive (Pneumococcal 21-valent conjugate vaccine). The vaccine is indicated to prevent invasive disease caused by a range of Streptococcus pneumoniae serotypes in adults,…
-
Sinovac Partners with Brazil’s Fiocruz to Boost Vaccine Research and Development
•
Fiocruz, a renowned health research center based in Brazil, has announced a collaboration agreement with China’s Sinovac Biotech Ltd. (NASDAQ: SVA) to jointly engage in the research and development of vaccines. The financial details of the partnership have not been disclosed. This collaboration comes on the heels of a meeting…
-
Sinovac Biotech Commits USD 100 Million Investment in Brazil for Vaccine Research and Collaboration
•
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading vaccine specialist based in China, is reportedly set to invest USD 100 million in the Brazilian market to bolster collaborations with local partners and researchers. The company plans to conduct in-country research not only on vaccines but also on advanced therapeutics, including cell…
-
AIM Vaccine Submits Pre-IND Applications for mRNA Vaccines Targeting RSV and Herpes Zoster to NMPA
•
AIM Vaccine Co., Ltd (HKG: 6660), a biopharmaceutical company based in China, has announced the submission of pre-Investigational New Drug (pre-IND) filings to China’s National Medical Products Administration (NMPA) for two of its mRNA vaccine candidates. These candidates target the respiratory syncytial virus (RSV) and herpes zoster, respectively. RSV infection…
-
Olymvax Bio Receives Ethical Approval for Oral Helicobacter pylori Vaccine Trial in Australia
•
Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced that it has received ethical approval for a Phase I study for its oral recombinant Helicobacter pylori (HP) vaccine (Escherichia coli) in Australia. The company has completed the clinical trial filing for this proprietary product.…
-
Sanofi Receives NMPA Approval for Phase III Clinical Trial of RSV Vaccine SP0125
•
Sanofi (EPA: SAN), a major French multinational pharmaceutical company, has announced that it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for SP0125, a nasal spray respiratory syncytial virus (RSV) attenuated live vaccine intended for use in infants and young children. RSV is among the most…
-
Olymvax Biopharmaceuticals Gets Green Light for Tetravalent Influenza Vaccine Clinical Trial
•
Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its tetravalent influenza virus split vaccine (MDCK cells). This vaccine is designed to prevent influenza caused by…
-
Sanofi Secures Novavax Vaccine Tech in a Deal Valued at Up to USD 1.2 Billion
•
France’s Sanofi (NASDAQ: SNY) has announced a strategic partnership with protein-based vaccines specialist Novavax (NASDAQ: NVAX), aiming to enhance its immunization portfolio. Under the agreement, Sanofi will gain access to Novavax’s Matrix-M adjuvant and secure exclusive rights to combine its influenza vaccines with Novavax’s SARS-CoV-2 vaccine. Sanofi will also co-commercialize…
-
WestGene Biopharma’s Groundbreaking mRNA Vaccine for EB Virus Tumors Gets FDA Green Light
•
WestGene Biopharma Co., Ltd., a biopharmaceutical company based in Chengdu, has announced that its drug candidate WGc-043 has been approved for clinical trials by the US Food and Drug Administration (FDA). WGc-043 is recognized as the world’s first clinically approved mRNA therapeutic vaccine targeting Epstein-Barr (EB) virus-related tumors. The vaccine…
-
Sirnaomics Partners with Hualan Biological to Develop and Commercialize RSV mRNA Vaccine in China
•
Sirnaomics Ltd (HKG: 2257) has entered into a strategic partnership with China’s Hualan Biological Engineering Inc., (SHE: 002007), to enhance the clinical development and commercialization of Sirnaomics’ respiratory syncytial virus (RSV) mRNA vaccine, RV-1770, in China. Under the agreement, Hualan will oversee clinical development, industrialization, and commercialization of the vaccine…
-
Former Sinopharm Executive Yang Xiaoming Removed from National People’s Congress Over Alleged Serious Violations
•
Yang Xiaoming, previously the chief engineer and chief scientist of China National Pharmaceutical Group Corporation (Sinopharm), has been dismissed from his role as a delegate to the 14th National People’s Congress due to suspicions of serious disciplinary and legal violations, as determined by the Standing Committee of the National People’s…
-
Clover Biopharmaceuticals Reports First Commercial Sales and Narrows Annual Loss in 2023
•
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced its financial results for 2023, recording its first commercial sales with revenues of RMB 39.3 million (USD 5.4 million). The revenues were driven by the COVID-19 vaccine SCB-2019 (CpG 1018/Alum) and the quadrivalent influenza vaccine AdimFlu-S (QIS), which were launched in China…
-
MSD Reports USD 15.8 Billion in Q1 2024 Sales, Marked by 11% YOY Growth Excluding Forex Impact
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has released its financial report for the first quarter of 2024, announcing sales of USD 15.8 billion, an increase of 11% year-on-year (YOY) excluding the impact of foreign exchange rates. The pharmaceutical division contributed USD 14.0 billion to the top line, with a…
-
CanSino Biologics Receives NMPA Approval for Haemophilus influenzae type B (Hib) Conjugate Vaccine Clinical Trial
•
China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its freeze-dried Haemophilus influenzae type B (Hib) conjugate vaccine. Haemophilus influenzae, a Gram-negative bacterium, is a leading cause of acute lower respiratory tract infections in children.…
-
Chongqing Zhifei Biological Reports 38.3% YOY Revenue Growth in 2023 Financial Results
•
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a biopharmaceutical company based in China, has released its financial report for 2023, recording revenues of RMB 52.918 billion (USD 7.3 billion), an increase of 38.3% year-on-year (YOY). Net profits for the company were reported at RMB 8.07 billion (USD 1.11 billion), marking…
-
GSK’s Shingrix Vaccine Maintains High Efficacy for Over a Decade, Phase III Data Show
•
GlaxoSmithKline (LON: GSK, NYSE: GSK), the UK-based pharmaceutical giant, has this week released long-term data from a follow-up Phase III trial of its recombinant herpes zoster vaccine, Shingrix. The vaccine demonstrated robust efficacy in adults aged 50 and above, with a 79.7% efficacy rate sustained from year 6 to year…
-
Kangtai Biological Receives NMPA Approval for 20-Valent Pneumococcal Vaccine Clinical Trial
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading biopharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its 20-valent pneumococcal polysaccharide conjugate vaccine. The vaccine is designed to prevent infectious diseases caused by…
-
Pfizer Reports Positive Phase III Results for RSV Vaccine Abrysvo in Younger Adults
•
Pfizer (NYSE: PFE) has announced interim results from a Phase III trial evaluating its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18 to 59 at risk of severe RSV-associated lower respiratory tract disease (LRTD). Currently, the vaccine is approved for preventing RSV-associated LRTD in older adults and for…
-
Clover Bio’s SCB-1019 Vaccine Candidate Shows Promising Results in Phase I Trial
•
Clover Biopharmaceuticals (HKG: 2197), a leading biotechnology company based in China, has announced robust preliminary data from the Phase I clinical trial of its bivalent RSV candidate vaccine, SCB-1019. The vaccine, which targets both RSV-A and RSV-B, demonstrated significant increases in neutralizing titers, a key indicator of immune response. Specifically,…
-
Walvax Biotechnology’s COVID-19 Variant Vaccine RQ3033 Shows Positive Phase III Results
•
China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has announced positive results from a Phase III immunogenic bridge study for its COVID-19 variant mRNA vaccine candidate, RQ3033, co-developed with Fudan University and RNACure. The vaccine is specifically targeting the Omicron XBB.1.5 variant and has demonstrated good efficacy and safety in the…
-
Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a prominent biopharmaceutical company based in China, has entered into a strategic agreement with UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) and the Daxing district government of Beijing. The collaboration is focused on the vaccine sector, aiming to introduce new vaccines to the…
-
CanSino Biologics Launches Phase III Study for Menhycia Vaccine in Indonesia
•
China-based CanSino Biologics (HKG: 6185) has announced the launch of a Phase III clinical study for its ACYW135 Meningococcal Conjugate Vaccine (CRM197), branded as Menhycia, in Indonesia, with the first subject already enrolled. This pivotal study aims to evaluate both the safety and immunogenicity of the vaccine in individuals aged…
-
Beijing Varnotech Biopharm Secures RMB 600 Million in Series B Funding for Vaccine Development
•
Beijing Varnotech Biopharm Ltd, a China-based specialist in human vaccines, has successfully raised RMB 600 million (approximately USD 83 million) in a Series B financing round. The round was co-led by the Beijing Medical and Health Industry Investment Fund and Huayin Financial Investment, with additional contributions from Watere Capital, Beijing…
-
CanSino Biologics Partners with Asymchem Laboratories to Innovate Biopharmaceutical Development
•
CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into a strategic partnership with Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a Contract Development and Manufacturing Organization (CDMO). This collaboration is designed to drive the development of cutting-edge technologies that align with market demands. The…
-
European Commission Approves Pfizer’s Prevenar 20 for Pediatric Use
•
The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its 20-valent pneumococcal vaccine, Prevenar 20, aimed at preventing invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae in individuals aged 6 weeks to 18 years. This vaccine was previously approved for use in adults…
-
Merck Plans Broader HPV Vaccine Development, Targeting African and Asian Populations
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled plans to develop a multi-valent human papillomavirus (HPV) vaccine aimed at providing broader protection than the currently approved 9-valent Gardasil 9. This new candidate will include additional virus-like particles (VLPs) targeting HPV types that disproportionately affect populations in Africa and Asia,…
-
GSK Reports US Adult Non-Flu Vaccination Rates Recover Post-Pandemic
•
GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reported that adult non-flu vaccination rates in the US have rebounded from the impact of the COVID-19 pandemic. According to data from GSK’s Vaccine Track platform, immunization rates between the first and third quarters of 2023 were…
-
AIM Vaccine Advances Pneumococcal Vaccine and Initiates Phase II Meningococcal Study
•
AIM Vaccine Co., Ltd (HKG: 6660) has delivered a series of updates on the development progress of its vaccine candidates. The company has submitted a preliminary market filing for its 13-valent pneumococcal conjugate vaccine, designed to prevent invasive diseases caused by 13 pneumococcal serotypes, including bacteremic pneumonia, meningitis, sepsis, and…
-
Pfizer’s RSV Vaccine Demonstrates Durable Efficacy with Abrysvo Phase III Results
•
Pfizer Inc. (NYSE: PFE) last week reported the outcomes of a Phase III trial for its respiratory syncytial virus (RSV) bivalent vaccine, Abrysvo, in adults aged 60 and above following the second RSV season. The vaccine’s efficacy against RSV-associated lower respiratory tract disease (LRTD) experienced a decline from 88.9% in…
-
Takeda Partners with Biological E to Boost Production of Dengue Vaccine QDenga
•
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has entered into an agreement with India-based Biological E (BE) with the aim of increasing production capacity for its dengue tetravalent vaccine, QDenga. This strategic partnership is part of Takeda’s broader plan to manufacture 100 million doses of the vaccine annually. QDenga,…
-
CanSino Biologics’ 13-Valent Pneumococcal Vaccine CRM197 Accepted for NMPA Review
•
CanSino Biologics Inc., (HKG: 6185), a leading Chinese biopharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted for review the New Drug Application (NDA) for its CRM197, a 13-valent pneumococcal polysaccharide conjugate vaccine (TT vector). This development marks a significant step forward in the advancement of…
-
Everest Medicines Terminates Agreement with Providence Therapeutics, Retains mRNA Rights
•
Everest Medicines (HKG: 1952), a biopharmaceutical company based in China, has announced the termination of a cooperation and licensing agreement with Providence Therapeutics (PTx), a Canadian RNA medicines company. Following the termination, Everest Medicines will independently continue the development of preventative and therapeutic mRNA products using the mRNA platform, holding…
-
FDA Grants Priority Review for GSK’s Arexvy to Expand RSV Vaccine Age Range to 50-59
•
The U.S. Food and Drug Administration (FDA) has initiated a priority review of GlaxoSmithKline’s (GSK; NYSE: GSK) application to extend the age range for its respiratory syncytial virus (RSV) vaccine, Arexvy, to include individuals aged 50 to 59 who are at increased risk for RSV disease. Arexvy was previously approved…
-
Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts
•
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the 9-month period ended December 31, 2023, reporting a revenue of JPY 3.2 trillion (USD 21.9 billion) with a 0.0% growth at constant exchange rates (CER). The company’s performance was impacted by declines in oncology, neuroscience,…
-
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
•
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth quarter and full-year 2023, with a 5% year-on-year (YOY) growth to GBP 30.3 billion (USD 38.5 billion) in revenue over the 12-month period. When excluding the impact of COVID-related products, the company’s sales surged by…
-
Kangtai Biological Products Co., Ltd. Expands Vaccine Access in South Asia with Bangladesh Deal
•
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a Chinese biopharmaceutical firm, has announced the signing of an authorized agency and technical transfer cooperation agreement with a company based in Bangladesh. The undisclosed Bangladeshi company will collaborate with Kangtai Bio on the 23-valent pneumococcal polysaccharide vaccine semi-finished stock solution. The…
-
Pfizer Reports USD 58.5 Billion in Revenues Amid Post-Pandemic Sales Shifts and Oncology Pipeline Expansion
•
Pfizer Inc. (NYSE: PFE) has reported a significant downturn in global revenues for the week, amounting to USD 58.5 billion, following a 41% year-on-year (YOY) decrease in operational terms. This substantial drop reflects the diminishing sales of the SARS-CoV-2 vaccine Comirnaty and the antiviral treatment Paxlovid. The reported figures align…
-
Wantai Biological Forecasts Sharp Drop in 2023 Net Profits Amid HPV Vaccine Sales Slump
•
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a Chinese pharmaceutical company, has issued a forecast for its 2023 performance, warning that net profits are expected to be within the range of RMB 1.2-1.35 billion (USD 169-190 million), marking a significant year-on-year (YOY) decrease of 74.66%-71.49%. The company’s sales…
-
GSK In-Licenses Elegen’s Cell-Free DNA Tech to Advance Next-Gen Gene Therapies and Vaccines
•
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has this week in-licensed US partner Elegen’s cell-free DNA manufacturing technology to bolster the potential development of next-generation mRNA, cell, and viral gene therapies, as well as RNA-based vaccines. Elegen will receive upfront fees, purchase commitments, potential equity investment, and milestone payments…
-
China Grand Pharmaceutical Gets NMPA Green Light for mRNA Cancer Vaccine ARC01 Phase I Study
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct an open-label, dosage escalation Phase I study for its therapeutic cancer vaccine ARC01 (A002). The study will assess the safety, tolerability, immunogenicity, pharmacokinetics, and…
-
Jiangsu Recbio Technology Strikes Licensing Deal with SPIMACO for 9-Valent HPV Vaccine
•
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a leading Chinese biotechnology company, has announced a strategic licensing and partnership agreement with Saudi Arabian pharmaceutical firm SPIMACO. The agreement pertains to Recbio’s recombinant 9-valent human papillomavirus (HPV) vaccine, REC603. Under the terms of the deal, SPIMACO will secure exclusive rights to…
-
Luzhu Biotechnology’s LZ901 Herpes Zoster Vaccine Trial Fully Enrolls 26,000 Participants
•
Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading manufacturer of human vaccines and therapeutic biologics, has declared the successful completion of patient enrollment for the Phase III clinical study of its vaccine candidate LZ901 in China. Over 98% of the participants have received the requisite two doses of either…
-
Zuellig Pharma Partners with Substipharm Biologics for Japanese Encephalitis Vaccine Distribution
•
Singapore-based healthcare company Zuellig Pharma has announced the establishment of a commercialization partnership with France-based Substipharm Biologics. The partnership centers around Substipharm’s Japanese encephalitis (JE) vaccine, Imojev. Zuellig Pharma will offer marketing and distribution support, aiming to make the vaccine accessible to patients across nine Asian markets, including Brunei, Cambodia,…
-
CanSino Biologics Enrolls First Patient in Phase I Trial of Innovative Polio Vaccine
•
CanSino Biologics (SHA: 688185, HKG: 6185), a China-based biotechnology firm, has announced the enrollment of its first patient in a Phase I clinical study for its recombinant polio vaccine in Australia. This candidate vaccine is a non-infectious virus-like particle (VLP) formulation, developed utilizing CanSino’s proprietary protein structure design and VLP…
-
Chengdu Kanghua Strikes Licensing Deal with HilleVax for Recombinant Norovirus Vaccine
•
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has entered into a licensing agreement with HilleVax Inc. (NASDAQ: HLVX), granting the US firm exclusive rights to develop, manufacture, and commercialize Kanghua’s recombinant hexavalent norovirus vaccine on a worldwide basis, excluding the Greater China region…
-
AstraZeneca Secures Exclusive Rights to Omniose’s Enzyme Platform for Bacterial Vaccine Development
•
AstraZeneca (AZ; NASDAQ: AZN) has secured an exclusive licensing agreement with biotechnology firm Omniose for up to three years, gaining access to Omniose’s enzyme-based bioconjugation platform. This platform will be utilized for the development of vaccines targeting bacterial pathogens, including those that are multidrug-resistant. Omniose’s proprietary enzyme technology enables the…
-
Jiangsu Recbio’s REC610 Shingles Vaccine Shows Positive Results in First-In-Human Study
•
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a Chinese biotechnology company, has announced positive results from the first-in-human (FIH) study for its novel adjuvanted recombinant shingles vaccine, REC610, which is being conducted in the Philippines. The study uses GlaxoSmithKline’s Shingrix (recombinant zoster vaccine; RZV), a major UK pharmaceutical company’s shingles…
-
Novo Nordisk Foundation Launches $260 Million Initiative to Develop Respiratory Disease Vaccines
•
Novo Nordisk Foundation, the entity that controls Denmark-based Novo Nordisk (CPH: NOVO-B), has unveiled an ambitious new initiative to bolster immunizations against respiratory diseases with a DKK 1.8 billion (USD 260 million) investment. This project, named the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI), aims to develop or…
-
Kangtai Biological Partners with Bahrain Pharma Firm on Strategic Vaccine Production Agreement
•
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a prominent player in China’s biotechnology sector, has entered into a supply and production licensing agreement with a leading pharmaceutical company based in Bahrain. This partnership focuses on a range of vaccines, including the 13-valent pneumococcal polysaccharide conjugate vaccine, the 23-valent pneumococcal…
-
Sirnaomics Ltd Granted FDA Approval for Phase I RSV mRNA Vaccine Study
•
Sirnaomics Ltd (HKG: 2257) has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I clinical study for its mRNA vaccine candidate RV-1770, targeting the respiratory syncytial virus (RSV) to prevent infections in adults. The study will involve the administration of three different doses (50mg,…
-
AstraZeneca Acquires Icosavax to Boost Infectious Disease Pipeline with VLP Vaccine Technology
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced the acquisition of US vaccines specialist Icosavax (NASDAQ: ICVX), including its protein virus-like particle (VLP) platform. AstraZeneca will pay approximately USD 800 million upfront for all outstanding shares, plus about USD 300 million in milestone payments. The acquisition is set to…
-
Clover Biopharmaceuticals Commences Phase I Trial for RSV Vaccine in Australia
•
China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the successful enrollment of the first batch of subjects in a Phase I clinical study in Australia for its pipeline candidate, SCB-1019, a respiratory syncytial virus (RSV) PreF trimeric subunit candidate vaccine. The randomized, placebo-controlled Phase I study aims to assess the…
-
Kangtai Biological Partners with Gennvax Egypt to Commercialize 13-Valent Pneumococcal Vaccine
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a Chinese biopharmaceutical company, has entered into an agency and technology transfer agreement with Egyptian firm Gennvax Egypt concerning Kangtai’s 13-valent pneumococcal polysaccharide conjugate vaccine. Under the terms of the agreement, the two companies will collaborate to advance the marketing approval of…
-
Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030
•
Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period, highlighting a pipeline of 12 assets poised to achieve blockbuster status, including three projected to exceed EUR 5 billion in sales. The French pharmaceutical giant anticipates generating over EUR 10 billion in annual pharmaceutical revenues…
-
Quinovare Partners with AIM Vaccine to Enhance Vaccine Accessibility in China
•
Quinovare Medical Technology Co., Ltd., a China-based specialist in needle-free injectors, has announced a strategic partnership with AIM Vaccine Co., Ltd. (HKG: 6660) to enhance the accessibility and affordability of vaccines through their combined resources and expertise. Financial terms of the collaboration were not disclosed. AIM Vaccine is a major…
-
Changchun BCHT Secures NMPA Approval for Freeze-Dried Human Rabies Vaccine Trials
•
Changchun BCHT Biotechnology Co., Ltd. (SHA: 688276), based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its freeze-dried human rabies vaccine, developed using human diploid/MRC-5 cells. This innovative vaccine utilizes human diploid cells, which are widely recognized in international…
-
Pfizer Allegedly Disbands Prevenar 13 Team in China Amid Industry Competition
•
Unconfirmed online reports suggest that Pfizer (NYSE: PFE) has dismissed its entire 400-person team for the Prevenar 13 vaccine in China, with the vaccine now reportedly under the management of local partner Kyuan, a subsidiary of pharmaceutical logistics giant Shanghai Pharma. The US pharmaceutical giant has been engaged in global…
-
Chinese Firms Secure EUAs for Omicron XBB Vaccines Amid Dominant Variant Surge
•
A wave of Chinese pharmaceutical companies has announced the receipt of Emergency Use Authorizations (EUAs) for their COVID-19 vaccines targeting the Omicron XBB variant. Among the notable developments are Lizhu Pharmaceutical’s (HKG: 1513) recombinant bivalent vaccine, which combines the prototype strain with the Omicron XBB variant, and CanSino Biologics’ (SHA:…
-
Merck’s V116 Pneumococcal Vaccine Shows Promising Data Against Pfizer’s Prevnar 20
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled new data from a late-stage trial of its 21-valent pneumococcal conjugate vaccine, V116, confirming earlier topline results. The data, released this week, highlights the vaccine’s immunogenicity, tolerability, and safety in comparison to Pfizer’s (NYSE: PFE) 20-valent Prevnar 20/Apexxnar in unvaccinated adults.…
-
DxVx Secures License for OVM-200 Anti-Cancer Vaccine from Oxford Vacmedix
•
South Korea-based DxVx is poised to license OVM-200 from Oxford Vacmedix (OVM), with plans to further develop the anti-cancer vaccine. OVM is anticipated to initiate a Phase Ib study for the vaccine in the UK in the near future, while DxVx will launch a study in Asia, encompassing South Korea…
-
Moderna Initiates Construction of First China-Based Pharmaceutical Plant in Shanghai
•
S-based mRNA specialist, Moderna (NASDAQ: MRNA), has commenced construction on its inaugural pharmaceutical facility in China, as reported by Xinhua. The new plant, situated in Shanghai’s Minhang District at the Xinzhuang Industry Park, is set to serve as Moderna’s China R&D and production headquarters. The project has attracted an investment…
-
Clover Biopharmaceuticals Submits Market Filing for Seasonal Influenza Vaccine in Brazil
•
China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the submission of a market filing for its seasonal influenza vaccine in Brazil. This move marks a strategic expansion for the company as it seeks to broaden the reach of its vaccine offerings. Product Details and AdvantagesThe product in question is a…
-
RinuaGene Receives US FDA IND Approval for HPV-Associated Tumor mRNA Vaccine RG002
•
RinuaGene, a leading mRNA specialist headquartered in Suzhou, has announced that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for its human papillomavirus (HPV) associated tumor therapeutic mRNA vaccine, RG002. This marks a significant step forward in the development of the vaccine,…
-
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
•
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third quarter of 2023, reporting a contraction of -41% year-on-year (YOY) in operational terms to USD 13.2 billion, excluding foreign currency fluctuations. The quarter was marked by a net loss of USD 2.38 billion, the company’s…
-
GSK Reports Modest 2% YOY Growth in Q3 2023 Finances, Vaccines Unit Soars 24%
•
UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third quarter of 2023, showing mixed results over the first three quarters. The company experienced a modest 2% year-on-year (YOY) expansion, reaching GBP 22.3 billion (USD 27.7 billion) at constant exchange rates. Vaccines Unit and General…
-
CSPC Pharmaceutical Group Gains NMPA Approval for Bivalent COVID-19 mRNA Vaccine Study
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its bivalent COVID-19 mRNA vaccine SYS6006.32, targeting the XBB.1.5 and BQ.1 variants. Vaccine Development and ImmunogenicitySYS6006.32 is…
-
Gates Foundation Funds CanSino’s Innovative Polio Vaccine Development
•
The Bill & Melinda Gates Foundation has announced a commitment of USD 2 million to support the development of CS-2036, a recombinant polio vaccine by China-based CanSino Biologics (SHA: 688185, HKG: 6185). This investment underscores the foundation’s dedication to global health initiatives and the eradication of polio. Innovative Approach to…
-
Walvax Biotechnology Secures BPOM Approval for Weuphoria Pneumococcal Vaccine
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received market approval from the Indonesian Food and Drug Control Agency (BPOM) for its Weuphoria, a 13-valent pneumococcal polysaccharide conjugate vaccine (PCV-13). This approval is a significant milestone for Walvax as it expands its reach into the Indonesian…
-
Changchun BCHT Biotechnology Invests in Influenza Vaccine Production Expansion
•
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced plans to invest RMB 805 million (USD 110 million) in the production of 10 million annual doses of its influenza virus split vaccine (BK-01 adjuvant). This substantial investment includes RMB 659 million for industrialization and RMB 146 million for operational…
-
Pfizer’s Penbraya Receives FDA Approval for Meningococcal Immunization
•
Pfizer Inc. (NYSE: PFE) announced last week that it has successfully registered its pentavalent meningococcal vaccine, Penbraya, with the US Food and Drug Administration (FDA). The vaccine is designed for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in individuals aged…
-
SciClone Pharmaceuticals Gains FDA Nod for Thymalfasin COVID-19 Vaccine Booster Study
•
SciClone Pharmaceuticals Inc. (HKG: 6600), formerly a US-based and Nasdaq-listed company, has announced that it has received approval from the US FDA to conduct a clinical study for its drug thymalfasin as a booster for COVID-19 mRNA vaccines. This marks a significant step in exploring new ways to enhance the…
-
Pfizer Adjusts 2023 Revenue Projections Amidst Decreased COVID-19 Solution Demand
•
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has revised its projected 2023 revenues downward, reflecting a decrease in demand for COVID-19 solutions. The new revenue projection falls between USD 58.0 billion and 61.0 billion, a significant adjustment from the previously anticipated range of USD 67.0 billion to 70.0 billion as reported…
-
Jiangsu Recbio Forms Strategic Cooperation for Vaccine Production in Zimbabwe
•
China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced a tripartite strategic cooperation agreement with the Zimbabwe National Biotechnology Authority (Zimbabwe NBA) and the International Centre for Genetic Engineering and Biotechnology China Regional Research Centre (ICGEB). This collaboration aims to enhance vaccine production capabilities in Zimbabwe, starting with the…
-
Beijing Launches Comprehensive Plan to Eliminate Cervical Cancer by 2030
•
The Beijing Municipal Health Commission, in collaboration with the Beijing Municipal Medical Insurance Bureau and seven other governmental bodies, has unveiled an “Implementation Plan for Accelerating the Elimination of Cervical Cancer in Beijing (2023-2030).” This ambitious campaign aims to significantly reduce cervical cancer incidence through a series of targeted preventive…
-
Chongqing Zhifei Partners with GSK for Shingrix Distribution in China
•
China-based Chongqing Zhifei Biological Co., Ltd. (SHE: 300122) has entered into a sole distribution and co-promotion agreement with UK pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) for its shingles vaccine, Shingrix (recombinant zoster vaccine; RZV). This partnership marks a significant step in enhancing the availability of Shingrix in the Chinese market.…
-
Janssen and Sanofi Partner for Development of First-in-Class E. coli Vaccine
•
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has entered into a strategic partnership with Sanofi (NASDAQ: SNY) to develop and commercialize a groundbreaking 9-valent vaccine targeting extraintestinal pathogenic Escherichia coli (ExPEC). Currently in late-stage trials, this vaccine aims to prevent invasive E. coli disease (IED) in adults…
-
CDC Provisionally Recommends Pfizer’s Abrysvo for Maternal Immunization Against RSV
•
The US Centers for Disease Control and Prevention (CDC) has issued a provisional recommendation for the use of Pfizer’s (NYSE: PFE) bivalent respiratory syncytial virus (RSV) vaccine, Abrysvo, as a seasonal maternal immunization strategy. This measure aims to prevent RSV lower respiratory tract infection in infants, a significant cause of…
-
AIM Vaccine’s Serum-Free Rabies Vaccine Completes Phase III Safety Observation
•
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the successful completion of the 7-day safety observation period in a Phase III clinical study for its investigational freeze-dried human rabies vaccine, developed using serum-free Vero cells. The study, which was conducted in a randomized, blinded, and similar vaccine parallel controlled…
-
Kangtai Biological Expands Global Reach with Varicella Vaccine Licensing Deals
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a China-based biopharmaceutical company, has entered into licensing agreements with undisclosed pharmaceutical companies in Pakistan and India. These strategic partnerships aim to strengthen the regulatory filing, marketing, and distribution of Kangtai Bio’s varicella attenuated live vaccines in both countries. Vaccine Description and…
-
Walvax Biotechnology Receives Indonesian FDA Approval for Phase III Pneumococcal Vaccine Trial
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received approval from the Food and Drug Supervisory Agency of Indonesia to initiate a Phase III clinical study for its Weuphoria, a 13-valent pneumococcal polysaccharide conjugate vaccine. Study Design and ObjectivesThe Phase III study is a randomized, blinded,…
-
CanSino Biologics Reports H1 2023 Revenues Down 96.7% YOY, COVID-19 Demand Decreases
•
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has released its financial report for the first half of 2023, recording revenues of RMB 21.09 million (USD 2.89 million), a decrease of 96.7% year-on-year (YOY). The contributions from China and overseas markets were RMB 17.93 million and RMB 3.16 million, respectively. The…
-
Chongqing Lummy Pharmaceutical’s Subsidiary Receives NMPA Approval for CUD002 mRNA Vaccine
•
Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006), through its subsidiary Sichuan Cunde Therapeutics Co., Ltd, has received clinical trial approval from the National Medical Products Administration (NMPA) for the CUD002 injection. This mRNA-edited DC (dendritic cell) tumor therapeutic vaccine product is based on patient tumor neoantigens, marking a significant step…
-
Jiangsu Recbio and Yikang Biological Partner to Develop RSV Preventative Vaccine
•
Jiangsu Recbio Technology Co., Ltd, a China-based biotechnology company, has entered into a product development cooperation agreement with Yikang Biological (Suzhou) Co., Ltd to develop a recombinant respiratory syncytial virus (RSV) vaccine aimed at preventing RSV-induced respiratory diseases. Under the terms of the agreement, Yikang will contribute its self-designed RSV…
-
Clover Biopharmaceuticals Launches AdimFlu-S, the Only Imported Quadrivalent Influenza Vaccine in China
•
China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the launch of AdimFlu-S (QIS) in mainland China, marking it as the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older. The vaccine has been listed in 26 provinces and municipalities across the country, gearing…
-
FDA Extends Pfizer’s Comirnaty Vaccine Indication for Omicron XBB.1.5 Variant
•
The US Food and Drug Administration (FDA) has granted Pfizer (NYSE: PFE) an indication extension for its SARS-CoV-2 Omicron XBB.1.5 single-dose monovalent vaccine, Comirnaty. The vaccine is now approved for individuals aged 12 years and older, in addition to receiving an emergency use authorization (EUA) for children between 6 months…
-
Sinovac Biotech Advances SA55 COVID-19 Neutralizing Antibody into Phase II Trials
•
China-based vaccines firm Sinovac Biotech Ltd (NASDAQ: SVA) has announced the completion of a Phase I trial and the immediate initiation of a Phase II study for its broad-spectrum COVID-19 neutralizing antibody, SA55. The molecule, which was first approved to enter clinical trials in China on May 24 this year,…
-
Latin America Accelerates COVID-19 Fight with Vaccine and Treatment Initiatives Across the Region
•
Latin America is ramping up its contributions to the worldwide race for COVID-19 vaccines and treatments. Cuba’s state-owned BioCubaFarma, through its Center for Genetic Engineering and Biotechnology (CIGB), has designed a vaccine candidate and is advancing its development in collaboration with China’s Research and Development Center in Yongzhou, Hunan’s Industrial…
